PALO ALTO, Calif., June 24 -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that in conjunction with the commercial launch of Lexiscan(TM) by Astellas Pharma US, Inc., CV Therapeutics has ...
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan Injection; Stocks Rise PALO ALTO, Calif., April 15 -- CV Therapeutics, Inc. announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results